Gaucher Patients Cope With Drug Shortage, as New Treatments Beckon

By Rebecca Dube

Published August 19, 2009, issue of August 28, 2009.
  • Print
  • Share Share

For thousands of people with Gaucher disease, the most common genetic disorder affecting Jews, the next few months will be challenging.

Many are going without the drug used to treat their potentially life-threatening enzyme disorder, after a virus contaminated a Boston-area manufacturing plant of biotechnology company Genzyme.

Meanwhile, Gaucher patients and their doctors are watching closely as the Food and Drug Administration is fast-tracking the approval process for two new treatments that would compete with Genzyme’s drug Cerezyme, which has had the market pretty much to itself until now.

“Of course there is anxiety,” said Rhonda Buyers, executive director of the National Gaucher Foundation. Because of the contamination at the Genzyme plant, supplies are limited and only the most vulnerable patients — children under 18 years old and adults with the most aggressive forms of the disease — are receiving regular doses of the drug. Everyone else has to wait until new doses of Cerezyme are available, which, according to Genzyme, may not be until November or December.

But there’s also hope, Buyers said. Partly in response to the plant contamination and drug shortage, the FDA has approved two new Gaucher drugs for limited compassionate and experimental use, one from the British-based pharmaceutical company Shire and another from Israel-based Protalix BioTherapeutics, raising the possibility that Gaucher patients won’t have to rely solely on Cerezyme in the future.

“If you have options, it’s just better than sitting there relying on one drug,” Buyers said.

Gaucher disease is caused by a genetic mutation, inherited from both parents, that results in a specific enzyme deficiency. According to Genzyme, fewer than 10,000 people worldwide have Gaucher disease. Symptoms may include enlargement of the liver and spleen, anemia, nose bleeds, easy bruising, bone pain and weakened bones. In the general population, about one in 100 people carry the gene for Gaucher disease; among Ashkenazic Jews, the carrier rate is one in 15. People can find out whether they carry the gene through a blood or saliva test.

Genzyme’s shutdown of its Allston, Mass., plant also stopped production of Fabrazyme, a drug to treat Fabry’s disease, another inherited enzyme disorder that causes lipid build-up in the body and increases the risk of heart attacks and strokes.

Kevin Kline of New Jersey was diagnosed with Gaucher disease when he was 5 years old, and he participated in the first clinical trials for the enzyme-replacement drug that eventually became Cerezyme. For the past 20 years, until last month, he has received injections of Cerezyme every two weeks; now he’s taking what he calls an “enzyme vacation.”

Kline, 37, hasn’t had any problems yet, and he is philosophical about the shortage.

“The Gaucher community is altruistic — we’re always looking out for each other,” he said. “People like myself are more than willing and capable of forgoing medication to help people who are more affected by the disease.”

People in the Gaucher community feel frustrated with Genzyme, he said, but at the same time Kline has a lot of gratitude for the fact that Cerezyme has been a “miracle” for him, allowing him to live basically symptom-free.

“It’s a tough situation,” Kline said. “While Genzyme has shown a lot of contrition, it doesn’t change the fact that we have a shortage.”

Like many other Gaucher patients, Kline and his doctor are monitoring his health and just waiting for Cerezyme to become available again this winter.

“We are in uncharted territory,” he said. “If I wake up one day and say, ‘Oh my God, I’m feeling the effects of not having the enzyme therapy,’ I’ll cross that bridge when I come to it.”


The Jewish Daily Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. In the interest of maintaining a civil forum, The Jewish Daily Forwardrequires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not. While we generally do not seek to edit or actively moderate comments, our spam filter prevents most links and certain key words from being posted and The Jewish Daily Forward reserves the right to remove comments for any reason.





Find us on Facebook!
  • The rose petals have settled, and Andi has made her (Jewish?) choice. We look back on the #Bachelorette finale:
  • "Despite the great pain and sadness surrounding a captured soldier, this should not shape the face of this particular conflict – not in making concessions and not in negotiations, not in sobering assessments of this operation’s achievements or the need to either retreat or move forward." Do you agree?
  • Why genocide is always wrong, period. And the fact that some are talking about it shows just how much damage the war in Gaza has already done.
  • Construction workers found a 75-year-old deli sign behind a closing Harlem bodega earlier this month. Should it be preserved?
  • "The painful irony in Israel’s current dilemma is that it has been here before." Read J.J. Goldberg's latest analysis of the conflict:
  • Law professor Dan Markel waited a shocking 19 minutes for an ambulance as he lay dying after being ambushed in his driveway. Read the stunning 911 transcript as neighbor pleaded for help.
  • Happy birthday to the Boy Who Lived! July 31 marks the day that Harry Potter — and his creator, J.K. Rowling — first entered the world. Harry is a loyal Gryffindorian, a matchless wizard, a native Parseltongue speaker, and…a Jew?
  • "Orwell would side with Israel for building a flourishing democracy, rather than Hamas, which imposed a floundering dictatorship. He would applaud the IDF, which warns civilians before bombing them in a justified war, not Hamas terrorists who cower behind their own civilians, target neighboring civilians, and planned to swarm civilian settlements on the Jewish New Year." Read Gil Troy's response to Daniel May's opinion piece:
  • "My dear Penelope, when you accuse Israel of committing 'genocide,' do you actually know what you are talking about?"
  • What's for #Shabbat dinner? Try Molly Yeh's coconut quinoa with dates and nuts. Recipe here:
  • Can animals suffer from PTSD?
  • Is anti-Zionism the new anti-Semitism?
  • "I thought I was the only Jew on a Harley Davidson, but I was wrong." — Gil Paul, member of the Hillel's Angels. http://jd.fo/g4cjH
  • “This is a dangerous region, even for people who don’t live there and say, merely express the mildest of concern about the humanitarian tragedy of civilians who have nothing to do with the warring factions, only to catch a rash of *** (bleeped) from everyone who went to your bar mitzvah! Statute of limitations! Look, a $50 savings bond does not buy you a lifetime of criticism.”
  • from-cache

Would you like to receive updates about new stories?




















We will not share your e-mail address or other personal information.

Already subscribed? Manage your subscription.